Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma – real world data from a retrospective multi-center analysis

Stelmach R., Schlack K., Neuberger S., Muehle C., Darr C., Reichert M., Flegar L.,Zengerling F., Casuscelli J., Cox A.,Nestler T., Egenolf T., Brehmer B., Vallet S.,Ivanyi P., Rehlinghaus M., Neuberger M.,Paffenholz P., Grünwald V.,Zschäbitz S.

European Urology Open Science（2023）

引用 0|浏览6

暂无评分

关键词

advanced renal cell carcinoma,renal cell carcinoma,pembrolizumab,lenvatinib,first-line,multi-center

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要